Eagle LogoPEPTIDE INITIATIVE

Peptide Database

Total Peptides: 32
Back to Home

PT-141

Bremelanotide

PT-141 (Bremelanotide) is an FDA-approved melanocortin receptor agonist specifically designed to treat hypoactive sexual desire disorder in premenopausal women. Unlike other sexual health treatments, PT-141 works through the central nervous system to enhance sexual desire and arousal rather than affecting blood flow or hormones.

Complete Research Database

0
Major Studies
0
Total Participants
3
Research Articles
N/A
Years of Research

Dual Receptor Mechanism (GIP/GLP-1)

GLP-1 Receptor Pathway

  • •Increases insulin secretion (glucose-dependent)
  • •Suppresses glucagon release
  • •Slows gastric emptying
  • •Enhances satiety in hypothalamus
  • •Preserves beta-cell function

GIP Receptor Pathway

  • •Enhances insulin secretion (stronger than GLP-1)
  • •Promotes fat oxidation
  • •Improves insulin sensitivity in muscle
  • •Reduces hepatic glucose production
  • •Modulates adipose tissue metabolism

Why Dual Agonism is Superior

PT-141 functions as a selective melanocortin-4 receptor (MC4R) agonist in the central nervous system. Upon subcutaneous administration, bremelanotide crosses the blood-brain barrier and binds to MC4R receptors in the hypothalamus and other limbic structures involved in sexual behavior. This activation triggers downstream signaling cascades involving cyclic adenosine monophosphate (cAMP) and protein kinase A pathways, ultimately enhancing sexual motivation and desire through neuronal mechanisms rather than peripheral vascular effects.

Pharmacokinetic Profile

~5 days
Half-life
8-72 hours
Tmax
80%
Bioavailability
99%
Protein binding
Proteolytic cleavage
Metabolism
Renal (primary)
Elimination

Top 10 High-Quality Research Articles

Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials

Read
Obstetrics & Gynecology (2019)
N = 2,514
High Impact
Significant improvement in sexual desire events and reduction in distress scores vs placebo
DOI: 10.1097/AOG.0000000000003124

Long-term Safety of Bremelanotide in Women with Hypoactive Sexual Desire Disorder

Read
Journal of Sexual Medicine (2020)
N = 2,400
High Impact
Acceptable long-term safety profile with no unexpected adverse events over 52 weeks
DOI: 10.1016/j.jsxm.2020.01.023

Melanocortin-4 Receptor Agonists for Sexual Dysfunction: Mechanisms and Clinical Applications

Read
Sexual Medicine Reviews (2021)
N = 0
Medium Impact
Comprehensive review of MC4R pathway in sexual function and therapeutic implications
DOI: 10.1016/j.sxmr.2021.03.002
Additional research available through PubMed and other scientific databases.

Medical Disclaimer

Clinical data presented is from peer-reviewed studies. Individual results may vary. Consult healthcare professionals before starting treatment. This information is for educational purposes only.